FY2022 · ended Dec 31, 2022 · Revenue $500,000, +0.0% YoY · Filed Mar 28, 2024
Imunon, Inc. (IMNN) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$14.2 million. As of Jun 30, 2026 it held $6.9 million in cash and investments and $811,190 in total debt.
Revenue
$500,000
+0.0% vs prior year
Net income
$-14.50M
+22.2% vs prior year
Operating cash flow (TTM)
$-15.11M
-5.8% vs year-ago TTM
Free cash flow (TTM)
$-15.18M
-4.2% vs year-ago TTM
EPS
$-6.83
+59.7% vs prior year
Dividend per share
None
Shares outstanding
3.92M
-73.2% vs prior year
Net cash
$6.05M
as of Jun 30, 2026
Operating margin
-4984.3%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMNN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Lawrenceville, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 749647
- Former names
- CELSION CORP (until Sep 19, 2022); Celsion CORP (until Sep 19, 2022); CHEUNG LABORATORIES INC (until Feb 17, 1998)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $500,000 | $500,000 |
| Operating income | -$14.7M | -$19.1M | -$21.0M | -$24.9M | -$21.0M |
| Net income | -$14.5M | -$18.6M | -$19.5M | -$35.9M | -$20.8M |
| Diluted EPS | -$6.83 | -$16.94 | -$2.16 | — | — |
| Operating cash flow | -$13.9M | -$18.9M | -$19.0M | -$23.1M | -$16.2M |
| Free cash flow | -$14.2M | -$18.9M | -$19.5M | -$23.4M | -$16.5M |
| Total assets | $12.3M | $9.7M | $21.9M | $44.0M | $74.0M |
| Total liabilities | $5.2M | $5.5M | $8.5M | $14.6M | $18.3M |
| Stockholders' equity | $7.1M | $4.2M | $13.4M | $29.3M | $55.8M |
| Cash and investments | $8.8M | $5.9M | $15.7M | $32.7M | $49.4M |
| Total debt | $1.0M | $1.1M | $1.6M | $6.2M | $779,619 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 27, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 21, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change
|
Sep 29, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
All 1001 Imunon, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.